Advertisement

Listen: With Genzyme, FDA Is 'Sending A Signal'

04:07
Download Audio
Resume

After nearly a year of production struggles, Cambridge-based Genzyme is facing growing pressure from shareholders and customers to catch up with demand for drugs to treat some rare genetic disorders. Genzyme is expecting federal regulators to levy a fine of at least $175 million for quality control problems at its manufacturing facility in Allston. The plant is back in operation, but Genzyme says it needs more time to get all of the needed medications out.

Gary Pisano, a professor of business administration at Harvard Business School, joined WBUR Friday morning to talk about quality control and the impact it could have at Genzyme.

This program aired on April 23, 2010.

Headshot of Bob Oakes

Bob Oakes Senior Correspondent
Bob Oakes was a senior correspondent in the WBUR newsroom, a role he took on in 2021 after nearly three decades hosting WBUR's Morning Edition.

More…

Advertisement

More from WBUR

Listen Live
Close